Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 9/2006

01-11-2006 | Original Paper

Associations among maternal soy intake, isoflavone levels in urine and blood samples, and maternal and umbilical hormone concentrations (Japan)

Authors: Chisato Nagata, Shinichi Iwasa, Makoto Shiraki, Tomomi Ueno, Shigeto Uchiyama, Koji Urata, Yukari Sahashi, Hiroyuki Shimizu

Published in: Cancer Causes & Control | Issue 9/2006

Login to get access

Absract

Objectives

In utero exposure to high levels of endogenous estrogens has been hypothesized to increase breast cancer risk in later life. A high intake of soy has been suggested to protect against breast cancer. We examined the hypothesis that maternal soy intake may be inversely associated with pregnancy hormone levels.

Methods

The concentrations of hormones (estradiol, estriol, and testosterone) and isoflavones (genistein, deidzein, and equol) were measured in the maternal urine and serum, and umbilical cord blood of 194 women during pregnancy and at delivery. Soy intake during pregnancy was assessed by 5-day diet records at approximately the 29th week of pregnancy.

Results

High correlations were observed for isoflavone levels between maternal samples and umbilical cord blood, indicating that isoflavone can be transferred from the maternal to the fetal compartment. None of the hormones measured in umbilical cord blood was significantly associated with any of the isoflavones measured. There were a few significant associations between maternal hormone levels and isoflavone measures during pregnancy, but their patterns of associations varied by gestational week and differed depending on whether isoflavone exposure was measured by diet records, urine or serum.

Conclusion

Our data contain no strong evidence showing that soy intake affects hormone levels during pregnancy.
Literature
1.
2.
Hsieh CC, Tzonou A, Trichopoulos D (1991) Birth order and breast cancer risk. Cancer Cause Control 2:95–98CrossRef
3.
Michels KB, Trichopoulos D, Robins JM, et al (1996) Birthweight as a risk factor for breast cancer. Lancet 48:1542–1546CrossRef
4.
Knopp RH, Bergelin RO, Wahl PW, Walden CE (1985) Relationships of infant birth size to maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries, and body weight at 36 weeks gestation. Diabetes 34:71–77PubMed
5.
Kaijser M, Granath F, Jacobsen G, Cnattingius S, Ekbom A (2000) Maternal pregnancy estriol levels in relation to anamnestic and fetal anthropometrics data. Epidemiology 11:315–319PubMedCrossRef
6.
Mucci LA, Lagiou P, Tamimi RM, Hsieh C-C, Adami H-O, Trichopoulos D (2003) Pregnancy estriol, estradiol, progesterone and prolactin in relation to birth weight and other birth size variables (United States). Cancer Cause Control 14:311–318CrossRef
7.
Peck JD, Hulka BS, Savitz DA, Baird D, Poole C, Richardson BE (2003) Accuracy of fetal growth indicators as surrogate measures of steroid hormone levels during pregnancy. Am J Epidemiol 157:258–266PubMedCrossRef
8.
9.
Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S (2003) Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 95:906–913PubMedCrossRef
10.
Grace PB, Taylor JI, Low Y-L, et al (2004) Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and Nutrition-Norfolk. Cancer Epidemiol Biomarkers Prev 13:698–708PubMed
11.
Pike AC, Brzozowski AM, Hubbard RE, et al (1999) Structure of the ligand-binding domain of estrogen receptor beta in the presence of a partial against and a full antagonist. EMBO J 18:4608–4618PubMedCrossRef
12.
Adlercreutz H, Yamada T, Wähälä K, Watanabe S (1999) Maternal and neonatal phytoestrogens in Japanese women during birth. Am J Obstet Gynecol 180:737–743PubMedCrossRef
13.
Le Bail J-C, Champavier Y, Chulia A-J, Habrioux G (2000) Effects of phytoestrogens on aromatase, 3β and 17β-hydroxysteroid dehydrogenanase activities and human breast cancer cells. Life Sci 66:1281–1291PubMedCrossRef
14.
Lu L-JW, Anderson KE, Grady JJ, Nagamani M (1996) Effects of soya consumption for one month on steroid hormones in premenopausal women:implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev 5:63–70PubMed
15.
Nagata C, Takatsuka N, Inaba S, Kawakami N, Shimizu H (1998) Effect of soymilk consumption on serum esrogen concentrations in premenopausal Japanese women. J Natl Cancer Inst 90:1830–1835PubMedCrossRef
16.
Wu AH, Stanczyk FZ, Hendrich S, et al (2000) Effects of soy foods on ovarian function in premenopausal women. Br J Cancer 82:1879–1886PubMedCrossRef
17.
Cassidy A, Bingham S, Setchell KDR (1994) Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 60:333–340PubMed
18.
Duncan AM, Merz BE, Xu X, Negel TC, Phipps WR, Kurzer MS (1999) Soy isoflavones exert modest hormonal effects in premenopausal women. J Clin Endocrinol Metab 84:192–197
19.
Shimizu H, Ohwaki A, Kurisu Y, et al (1999) Validity and reproducibility of a quantitative food frequency questionnaire for a cohort study in Japan. Jpn J Clin Oncol 29:38–44PubMedCrossRef
20.
Nagata C, Takatsuka N, Kawakami N, Shimizu H (2001) Soy product intake and hot flashes in Japanese women: results from a community-based prospective study. Am J Epidemiol 153:790–793PubMedCrossRef
21.
Coward L, Kirk M, Albin N, Barnes S (1996) Analysis of plasma isoflavones by reversed-phase HPLC-multiple reaction ion monitoring-mass spectrometry. Clin Chim Acta 247:121–142PubMedCrossRef
22.
Lundh TJ, Pettersson H, Kiessling KH (1988) Liquid chromatographic determination of estrogens daidzein, formononetin, coumestrol, and equol in bovine blood plasma and urine. J Assoc Off Anal Chem 7:938–941
23.
Willett W (1990) Implication of total energy intake for epidemiological analyses. In: Willett W (ed) Nutritional epidemiology. Oxford University Press, Oxford, pp 245–271
24.
Harrison RM, Phillippi PP, Swan K, Henson MC (1999) Effect of genistein on steroid hormone production in the pregnant rhesus monkey. OSEBM 222:78–84
25.
Steele VE, Pereira MA, Sigman CC, Keloff GJ (1995) Cancer chemopreventive agent development strategies for genistein. J Nutr 125:713S–716SPubMed
26.
Hilakivi-Clarke L, Cho E, Cabanes A, et al (2002) Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring. Clin Cancer Res 8:3601–3610PubMed
27.
Awoniyi CA, Roberts D, Veeramachaneni DNR, Hurst BS, Tucker KE, Sclaff WD (1998) Reproductive sequelae in female rats after in utero and neonatal exposure to the phytoestrogen genistein. Fertil Steril 70:440–447PubMedCrossRef
28.
Takagi H, Shibutani M, Lee K-Y, et al (2004) Lack of modyfying effects of genistein on disruption of the reproductive system by perinatal dietary exposure to ethinylestradiol in rats. Reprod Toxicol 18:687–700PubMedCrossRef
29.
Nagata C, Kabuto M, Kurisu Y, Shimizu H (1997) Decreased serum estradiol concentration associated with high dietary intake of soy products in premenopausal Japanese women. Nutr Cancer 29:228–233PubMedCrossRef
30.
Nagata C, Takatsuka N, Kawakami N, Shimizu H (2000) Total and monounsaturated fat intake and serum estrogen concentrations in premenopausal Japanese women. Nutr Cancer 38:37–39PubMedCrossRef
31.
Yamamoto S, Sobue T, Sasaki S, et al (2001) Validity and reproducibility of a self-administered food-frequency questionnaire to assess isoflavone intake in a Japanese population in comparison with dietary records and blood and urine isoflavones. J Nutr 131:2741–2747PubMed
32.
Lampe JW, Karr SC, Hutcins AM, Slavin J (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. PSEBM 217:335–339
33.
Morito K, Hirose T, Kinjo J, et al (2001) Interaction of phytoestrogens with estrogen receptor α and β. Biol Pharm Bull 24:351–356PubMedCrossRef
34.
Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, Kurzer M (2000) Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9:581–586PubMed
Metadata
Title
Associations among maternal soy intake, isoflavone levels in urine and blood samples, and maternal and umbilical hormone concentrations (Japan)
Authors
Chisato Nagata
Shinichi Iwasa
Makoto Shiraki
Tomomi Ueno
Shigeto Uchiyama
Koji Urata
Yukari Sahashi
Hiroyuki Shimizu
Publication date
01-11-2006
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 9/2006
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-006-0044-4

Other articles of this Issue 9/2006

Cancer Causes & Control 9/2006 Go to the issue

Original Paper

Meeting the mammography screening needs of underserved women: the performance of the National Breast and Cervical Cancer Early Detection Program in 2002–2003 (United States)

Original Paper

Genetic polymorphisms in anti-inflammatory cytokine signaling and the prevalence of gastric precancerous lesions in Venezuela

Original Paper

A prospective study of fish, marine fatty acids, and bladder cancer risk among men and women (United States)

Brief Report

Folate, vitamin B12 and postmenopausal breast cancer in a prospective study of French women

Original paper

Oral contraceptive use and risk of breast carcinoma in situ (United States)

Original Paper

NAT2, meat consumption and colorectal cancer incidence: an ecological study among 27 countries
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits